- Conditions
- Healthy Volunteers
- Interventions
- AG-181, Placebo
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 738
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ulcerative Colitis
- Interventions
- UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Greenville, North Carolina • Salt Lake City, Utah
- Conditions
- Covid19
- Interventions
- Part A: Upamostat 200 mg, Part A: Upamostat 400 mg, Part A and B: Placebo, Part B: Upamostat 200 or 400 mg
- Drug
- Lead sponsor
- RedHill Biopharma Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 11
- States / cities
- Cutler Bay, Florida • Hialeah, Florida • Miami, Florida + 7 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 20
- States / cities
- Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
- Conditions
- Acute Myeloid Leukaemia (AML)
- Interventions
- Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.
- Drug
- Lead sponsor
- Moleculin Biotech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Miami, Florida • Augusta, Georgia + 5 more
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B)
- Drug · Other
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 32
- States / cities
- Chula Vista, California • Garden Grove, California • Los Angeles, California + 28 more
- Conditions
- Healthy Volunteers, Chronic Kidney Disease
- Interventions
- IGT-303, Placebo
- Drug
- Lead sponsor
- Ingenia Therapeutics INC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Lakeland, Florida • Statesville, North Carolina + 1 more
- Conditions
- Solid Tumor
- Interventions
- 7HP349 Single Ascending Dose, 7HP349 Multiple Ascending Dose, Placebo Single Ascending Dose, Placebo Multiple Ascending Dose, 7HP349 Food Effect
- Drug
- Lead sponsor
- 7 Hills Pharma, LLC
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
- Interventions
- Litifilimab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 62
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
- Conditions
- Sleep Apnea
- Interventions
- Sivopixant, Placebo, Acetazolamide, SASS-001
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 9
- States / cities
- La Jolla, California • Brandon, Florida • Miami, Florida + 6 more
- Conditions
- Atopic Dermatitis
- Interventions
- Tezepelumab, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 16
- States / cities
- Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- ALN-CIDEB, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Chandler, Arizona • Tucson, Arizona
- Conditions
- Diabetic Nephropathy
- Interventions
- CTP-499
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Kidney Failure, Chronic
- Interventions
- LY3113593, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Glendale, California • Orlando, Florida • Minneapolis, Minnesota
- Conditions
- COVID-19
- Interventions
- mRNA-CR-04 vaccine 10μg, mRNA-CR-04 vaccine 30μg, mRNA-CR-04 vaccine 100μg, Placebo, mRNA-CR-04 vaccine 3μg
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- San Diego, California • Melbourne, Florida • Peoria, Illinois + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- BGB-23339, Placebo
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Alzheimer Disease
- Interventions
- Citicoline supplement, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab 10 mg/kg, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more
- Conditions
- Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Interventions
- ALN-PNP, Placebo (PB)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 6
- States / cities
- Glendale, California • Los Angeles, California • Miami, Florida + 2 more
- Conditions
- Overweight, Obesity
- Interventions
- UBT251, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Cypress, California • Overland Park, Kansas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK1292263, GSK1292263 matching placebo, Sitagliptin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Chula Vista, California • Miami, Florida
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- Empasiprubart IV, Placebo IV
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Rancho Mirage, California + 10 more
- Conditions
- Healthy
- Interventions
- Placebo, LY3039478 Capsule Formulation (Formulation 3), LY3039478 Drug-in Capsule (Reference, Formulation 1), LY3039478 Formulated Capsule (Test, Formulation 3)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Healthy Volunteers
- Interventions
- S-337395, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas